This phase II trial is testing whether combining niraparib (a PARP inhibitor) and dostarlimab (an immunotherapy) can shrink or control recurrent or persistent uterine serous carcinoma. The study enrolled 8 women whose cancer had returned after standard chemotherapy. Researchers a…
Phase: PHASE2 • Sponsor: Casey Cosgrove • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC